Last $35.15 USD
Change Today -0.85 / -2.36%
Volume 1.5M
SGEN On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - seattle genetics inc (SGEN)

Name (Connections)Board RelationshipsTitleKey Developments
John McLaughlin J.D. 23 RelationshipsDirector, Member of Audit Committee and Member of Compensation Committee 
John Orwin 141 RelationshipsDirector and Member of Audit Committee 

Compensation Committee* - seattle genetics inc (SGEN)

Name (Connections)Board RelationshipsTitle
Felix Baker Ph.D. 36 RelationshipsLead Independent Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee
John McLaughlin J.D. 23 RelationshipsDirector, Member of Audit Committee and Member of Compensation Committee
SGEN Compensation vs. Industry
722.9K
319.0K
Chief Executive Officer
397.0K
230.6K
Chief Financial Officer
456.3K
287.8K
Chief Operating Officer
Share price activity for SEATTLE GENETICS INC (SGEN)
52 Week Price Performance
SGEN
Industry Average

Nominating Committee* - seattle genetics inc (SGEN)

Name (Connections)Board RelationshipsTitleKey Developments
Felix Baker Ph.D. 36 RelationshipsLead Independent Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance CommitteeSeattle Genetics Inc. Announces Executive Changes
11/18/14
Nancy Simonian M.D. 26 RelationshipsDirector and Chairman of Nominating & Corporate Governance CommitteeSeattle Genetics Inc. Announces Resignation of Franklin M. Berger as Board of Directors
03/28/14
Marc Lippman M.D. 9 RelationshipsDirector and Member of Nominating & Corporate Governance CommitteeSeattle Genetics Announces Executive Promotions and Management Addition
02/10/14

Corporate Governance Committee* - seattle genetics inc (SGEN)

Name (Connections)Board RelationshipsTitle
Felix Baker Ph.D. 36 RelationshipsLead Independent Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee
Marc Lippman M.D. 9 RelationshipsDirector, Member of Audit Committee and Member of Compensation Committee
Nancy Simonian M.D. 26 Relationships--
SGEN and Competitor
Insiders vs. External
Board
11%
89%
Seattle Genetics Inc.
22%
78%
Ariad Pharmaceuticals Inc.
0%
100%
Morphosys AG
0%
100%
Genmab A/S
50%
50%
Pfizer Limited
29%
71%
INSYS Therapeutics, Inc.
Insiders
External Board Members
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGEN:US $35.15 USD -0.85

SGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $7.95 USD -0.08
Genmab A/S kr514.50 DKK -4.00
Insys Therapeutics Inc $55.98 USD +0.10
MorphoSys AG €72.70 EUR -0.76
Pfizer Ltd/India 2,032 INR +18.40
View Industry Companies
 

Industry Analysis

SGEN

Industry Average

Valuation SGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.6x
Price/Book 21.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEATTLE GENETICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.